Chimerix to Present at Virtual H.C. Wainwright BioConnect 2022 Conference
January 03, 2022 16:45 ET
|
Chimerix, Inc.
DURHAM, N.C., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of...
Chimerix Announces Positive ONC201 Data in Recurrent H3 K27M-mutant Diffuse Midline Glioma to Be Presented at the Society for Neuro-Oncology Annual Meeting
November 19, 2021 07:00 ET
|
Chimerix, Inc.
– Plenary Session Presentation on Saturday, November 20 – – Company to Host Conference Call at 8:30 a.m. ET on Monday, November 22 – DURHAM, N.C., Nov. 19, 2021 (GLOBE NEWSWIRE) --...
Chimerix to Present at Jefferies London Healthcare Conference
November 12, 2021 08:00 ET
|
Chimerix, Inc.
DURHAM, N.C., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX),a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients...
Chimerix Announces Upcoming Presentations at the Society for Neuro-Oncology Annual Meeting 2021
November 11, 2021 07:00 ET
|
Chimerix, Inc.
DURHAM, N.C., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of...
Chimerix Reports Third Quarter 2021 Financial Results and Provides Operational Update
November 04, 2021 07:05 ET
|
Chimerix, Inc.
– Announced Positive Topline Results from ONC201 in Recurrent H3 K27M-mutant Glioma – –U.S. Food and Drug Administration (FDA) Published Article Summarizing Benefit-Risk Assessment of TEMBEXA for...
Chimerix Announces Positive Topline Results for ONC201 in Recurrent H3 K27M-mutant Glioma
November 04, 2021 07:00 ET
|
Chimerix, Inc.
– Blinded Independent Central Review (BICR) of ONC201 Cohort Reported 20.0% Objective Response Rate (ORR) by RANO-HGG Criteria – – Compelling Durability of Responses with 11.2 Month Median Duration...
Chimerix to Present at Credit Suisse 30th Annual Healthcare Conference
November 01, 2021 08:00 ET
|
Chimerix, Inc.
DURHAM, N.C., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients...
Chimerix to Report Third Quarter 2021 Financial Results and Provide an Operational Update on November 4, 2021
October 28, 2021 07:00 ET
|
Chimerix, Inc.
DURHAM, N.C., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing medicines for patients facing deadly diseases that meaningfully improves and extends...
Chimerix to Present at H.C. Wainwright 23rd Annual Global Investment Conference
September 07, 2021 07:00 ET
|
Chimerix, Inc.
DURHAM, N.C., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases,...
Chimerix Reports Second Quarter 2021 Financial Results and Provides Operational Update
August 05, 2021 07:00 ET
|
Chimerix, Inc.
– Received U.S. Food and Drug Administration (FDA) Approval for TEMBEXA® (brincidofovir) for the Treatment of Smallpox – – Blinded Independent Central Review (BICR) of ONC201 Registration Cohort in...